Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation

Thrombosis Research

Volumn 106, Issue 1, 2002, Pages 59-62

  Antovic, Jovan P ^a   Blombäck, Margareta ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

APC resistance; FV Leiden; Plasma procarboxypeptidase B; Procarboxypeptidase U; TAFI activity; TAFI antigen

Indexed keywords

ANTIGEN; BLOOD CLOTTING FACTOR 5 LEIDEN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR ANTIGEN; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 5; CARBOXYPEPTIDASE; CARBOXYPEPTIDASE B; CHROMOGENIC SUBSTRATE; ENZYME PRECURSOR;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOWN REGULATION; FEMALE; FIBRINOLYSIS; GENE MUTATION; HETEROZYGOSITY; HUMAN; LUNG EMBOLISM; PRIORITY JOURNAL; RISK FACTOR; BLOOD; CASE CONTROL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; MIDDLE AGED; VEIN THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; CARBOXYPEPTIDASE B; CARBOXYPEPTIDASE U; CARBOXYPEPTIDASES; CASE-CONTROL STUDIES; CHROMOGENIC COMPOUNDS; ENZYME PRECURSORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR V; FEMALE; FIBRINOLYSIS; HUMANS; MIDDLE AGED; PULMONARY EMBOLISM; VENOUS THROMBOSIS;

EID: 0036544774     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00072-5     Document Type: Article

References (20)

1. Plasma carboxypeptidases as regulators of the plasminogen system
2. Purification and characterization of TAFI, a thrombin activable fibrinolysis inhibitor
3. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex
4. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B
5. A study of the mechanism of inhibition of fibrinolysis by activated thrombin activable fibrinolysis inhibitor
6. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease
7. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease
8. Thrombin activatable fibrinolysis inhibitor and the risk of deep vein thrombosis
9. Reduced activity of TAFI (thrombin-activable fibrinolysis inhibitor) in acute promyelocytic leukaemia
10. Mutation in blood coagulation factor V associated with resistance to activated protein C
11. Factor V Leiden and the risk for thromboembolic disease: A clinical perspective
12. Incidence of venous thromboembolism in families with inherited thrombophilia
13. Elevated levels of prothrombin activation fragment 1+2 in plasma of patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance)
14. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent
15. Plasma TAFI antigen variations in healthy subjects
16. CPR total (TAFI and activated TAFI) levels in plasma/serum of hemophiliacs
17. Total thrombin activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with hemophilia A
18. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V Leiden
19. Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C
20. A simple and rapid laboratory method for determination of haemostasis potential in plasma: II. Modifications for use in routine laboratories and research work